Basel, Switzerland, November 20 (ots/PRNewswire) - - Annals of Oncology Paper Suggests That Oral Agents Such as Xeloda, Which are Proven to be Equally Effective and Have a Tolerable Side Effect Profile, Should Replace Traditional Intravenous Chemotherapy A review paper in Annals of Oncology now ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information 19.11.2007 Extraordinary general meeting to confirm statutory restrictions on share registration D i e t l i k o n, 19 November 2007 - The Board of Directors of ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information 19.11.2007 Extraordinary general meeting to confirm statutory restrictions on share registration D i e t l i k o n, 19 November 2007 - The Board of Directors of ...
. Profit after tax up 130 percent to over EUR 38 million . Total Group revenues up 22 percent to EUR 891 million . Full-year 2007 profit forecast reaffirmed ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. companies Schrobenhausen (euro adhoc) - Schrobenhausen, November 14, 2007 - Against a background of positive market conditions, BAUER ...
San Diego, November 8 (ots/PRNewswire) - - Fiscal 2007 Revenues US$8.87 Billion, Diluted EPS US$1.95 - Pro Forma Fiscal 2007 Revenues US$8.87 Billion, Diluted EPS US$2.01 - Worldwide 3G Adoption Drives Record Fiscal Year Financial Results Qualcomm Incorporated (Nasdaq: QCOM) today announced results for the fourth fiscal quarter and year ended September 30, 2007. Total Qualcomm (GAAP) Results ...
St. Peter Port, Guernsey, Channel Islands, November 6 (ots/PRNewswire) - - Reiterates Q4 Dividend Guidance of euro 0.14 European Capital Limited ("European Capital") (LSE: ECAS) announced today its fourth quarter 2007 dividend guidance and its results for the third quarter of 2007. FOURTH QUARTER 2007 DIVIDEND GUIDANCE European Capital reiterates ...
Shire Pharmaceuticals Group Plc
Basingstoke, England, November 5 (ots/PRNewswire) - - For global distribution excluding the US and Canada New data presented today at the 40th annual American Society of Nephrology (ASN) meeting and scientific exposition in San Francisco, CA, USA, show that epoetin delta - the only erythropoiesis-stimulating agent (ESA) produced in a human cell line - has ...
Basel, Switzerland, November 5 (ots/PRNewswire) - -Low Haemoglobin Levels Associated With Increased Risk of Cardiovascular Disease and Death Data from the analysis of six major trials for the innovative new renal anaemia treatment MIRCERA, have shown that it effectively corrects and maintains haemoglobin ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information 02.11.2007 D i e t l i k o n, 2 November 2007 - The Board of Directors of Implenia AG is aware of the preliminary notification published this morning of a public offer to acquire the entire share capital of Implenia AG. Its ...
Basel, Switzerland (ots/PRNewswire) - A new study on pain published today has found that subcutaneous (SC) injections of the new renal anaemia therapy MIRCERA is associated with significantly less pain immediately after injection than SC darbepoetin-alfa (Aranesp).(1) These findings are important because to date there has been minimal data regarding SC injection ...
Vienna, Austria (ots/PRNewswire) - Valdoxan(R) (agomelatine), the first melatonergic antidepressant, is an effective, long-term treatment for Major Depressive Disorder (MDD) according to new data presented today at the European College of Neurospsychopharmacology (ECNP) annual congress. The new international ...
Aachen (ots) - At this year's 4th World Congress of the World Institute of Pain (WIP), the German pharmaceutical company Grunenthal GmbH presented the latest clinical data on its centrally active analgesic tapentadol in acute pain. Tapentadol combines two analgesic principles in one molecule, μ-receptor ...
San Jose, California (ots/PRNewswire) - - Transparent Internal Calibration Improves Performance without Disrupting Operation and Cuts Cost by Eliminating the Need for External Calibration Circuitry or Calibration Software Atmel(R) Corporation (Nasdaq: ATML) announced today the third of its MAX-Link(TM) series of transceivers designed specifically for WiMAX ...
San Diego (ots/PRNewswire) - - Increases Fourth Fiscal Quarter and Fiscal 2007 Earnings Per Share Estimates Qualcomm Incorporated (Nasdaq: QCOM) today updated its financial guidance for the fourth fiscal quarter and fiscal year ending September 30, 2007. The following statements are forward looking ...
San Diego (ots/PRNewswire) - - Increases Fourth Fiscal Quarter and Fiscal 2007 Earnings Per Share Estimates Qualcomm Incorporated (Nasdaq: QCOM) today updated its financial guidance for the fourth fiscal quarter and fiscal year ending September 30, 2007. The following statements are forward looking ...
Barcelona, Spain (ots/PRNewswire) - Abstract no: 1LB, being presented at ECCO "Gastrointestinal malignancies - colorectal cancer 1" session in room 110, starting at 09.00 on Tuesday 25 September 2007 BARCELONA, Spain, September 25 /PRNewswire/ -- - 5 Year Data Confirm Superiority of Xeloda Over the Mayo Clinic Regimen in Treating Colon Cancer Five-year follow-up data from the X-ACT trial presented today ...
Barcelona, Spain (ots/PRNewswire) - Abstract no: 1LB, being presented at ECCO "Gastrointestinal malignancies - colorectal cancer 1" session in room 110, starting at 09.00 on Tuesday 25 September 2007 BARCELONA, Spain, September 25 /PRNewswire/ -- - 5 Year Data Confirm Superiority of Xeloda Over the Mayo Clinic Regimen in Treating Colon Cancer Five-year follow-up data from the X-ACT trial presented today ...
Barcelona, Spain (ots/PRNewswire) - - Largest Series of Patients With Successful Surgery Reported in Large, Prospective Clinical Trial - Abstract no: 3020, Being Presented at ECCO in Room 115-116, Starting at 12:15 on Monday 24th September 2007 - For non-US Media Only New data from the large international First BEAT trial unveiled today at the ...
Honolulu, Hawaii (ots/PRNewswire) - - Protelos(R) Relaunches Bone Formation and Increases Bone Volume in Patients on Long Term Bisphosphonate Treatment Protelos(R) (strontium ranelate) stimulates bone formation and increases bone volume by 30% in high fracture risk patients who have been on long term ...
Alliance for Better Bone Health
Honolulu, Hawaii (ots/PRNewswire) - New data show that Actonel(R) 5mg (risedronate sodium tablets) reduces the risk of clinical fractures by half versus placebo over three years in postmenopausal women with osteoporosis who have suffered a previous hip fracture(1)- a group of patients at high risk of a subsequent fracture. These results are from a retrospective ...
Basel, Switzerland (ots/PRNewswire) - - PROPHESYS Will Identify Factors That Influence Early Response to Treatment Roche announces the start of a large multinational observational study, called PROPHESYS, in patients with hepatitis C (HCV). This international cohort study will evaluate the important factors that give hepatitis C patients the best chance of treatment success with PEGASYS(R) (peginterferon ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 6-month report 13.09.2007 D i e t l i k o n, 13 September 2007 - The Implenia Group, created with the merger of the two most important Swiss construction companies, Zschokke and Batigroup, ...
Ingelheim, Germany (ots/PRNewswire) - - New Data on BIBW 2992(i), a Potent, Irreversible, Second-Generation Oral Signal Transduction Inhibitor Provides Glimpse of Next Chapter in Lung Cancer Care - For Non-US Media Boehringer Ingelheim announced today from the 12th World Conference on Lung Cancer (WCLC) that the company plans to commence Phase III ...
Seoul, Korea (ots/PRNewswire) - Patients worldwide with advanced lung cancer can expect longer survival according to new data from the TRUST study presented at the 12th World Conference on Lung Cancer (WCLC) in Seoul, Korea. These new worldwide observations show that patients suffering from non-small cell lung cancer (NSCLC) and treated with Tarceva (erlotinib) in routine clinical practice are experiencing ...
Ingelheim, Germany (ots) - For scientific media outside the USA, Canada and Japan Boehringer Ingelheim announced today that it is undertaking a new initiative in the treatment of heart attack (ST-segment elevation myocardial infarction or STEMI). The company will sponsor a new clinical trial known as ...
Heilbronn, Germany (ots/PRNewswire) - - Industry's Only Device Integrating Voltage Regulator, Window Watchdog, and LIN Transceiver in One Package Atmel(R) Corporation (Nasdaq: ATML) announced today the availability of its new ATA6823 H-bridge driver IC designed using Atmel's state-of-the-art 0.8-um BCD-on-SOI technology (SMARTIS(TM)). The ATA6823 provides ...
Ingelheim, Germany (ots/PRNewswire) - Constipation is a condition that we are all familiar with, however, according to new international research from Dulcolax(R), constipation actually affects much more than just bowel movements and can have a severely detrimental impact on people's quality of life, in some cases comparable to that experienced by people suffering from more serious ailments. The Dulcolax(R) survey ...
Paris (ots/PRNewswire) - Sanofi-aventis announced today that one year findings from the landmark ExTRACT-TIMI 25 and STEEPLE studies confirm clear net clinical benefit for patients with acute ST-segment elevation myocardial infarction (STEMI) for Lovenox(R) vs Unfractionnated Heparin (UFH). The ExTRACT-TIMI ...
Basel, Switzerland (ots/PRNewswire) - - First Medicine Shown to Extend Survival Beyond One Year in Previously Untreated Lung Cancer Patients Avastin (bevacizumab), Roche's innovative anti-cancer drug, was approved today in Europe for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), in combination with platinum-based ...
St. Peter Port, Guernsey, Channel Islands (ots/PRNewswire) - In the news release, European Capital (Nasdaq: ACAS) Increases Q3 Dividend 30% to euro 0.13, issued earlier today by European Capital Limited over PR Newswire, was incorrectly transmitted by PR Newswire, the complete, corrected release follows: ST. PETER PORT, Guernsey, Channel Islands, August 22 /PRNewswire/ -- European Capital Increases Q3 ...